Hellerup, Denmark, February 9, 2021 – UNION therapeutics A/S (“UNION”), a privately held, clinical stage pharmaceutical company, today announced the completion of a 155m DKK financing round from a group of existing and new investors.
The proceeds enable accelerated development of UNION’s clinical programs, and in particular offers an opportunity for UNION to support international patient studies for which UNI91103 (nasal spray) and UNI91104 (inhalation treatment) have been invited by government sponsored COVID-19 platform trial committees.
Morten Boesen, Chief Financial Officer of UNION commented: “UNION has experienced tremendous growth and advancements in our clinical pipeline during 2020. With the selection into international COVID-19 patient studies, UNION is entering a new stage of development. We are honored and proud to support these studies and the development of treatment options for COVID-19 patients.”
Rasmus Toft-Kehler, Co-founder and Chief Operating Officer, further added; “The UNION team successfully advanced two drug development programs from idea to registration studies in 2020 and both team and momentum has continued to rapidly build as we entered 2021. With additional funds available, Dr. Kim Kjoeller in place as our new CEO, and four clinical product candidates in mid- to late stage development, UNION is set for an exciting 2021.”
About UNION:
UNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The Company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and USA. For more information please visit www.uniontherapeutics.com.
